The use of 3D Bioprinting to achieve uniformity and reproducibility of in vitro skin models
Tags: Skin model
Register for our upcoming free webinar on 3D bioprinting and learn how you can achieve uniformity and reproducibility of in vitro skin models for future pharmaceutical research and clinical applications.
Date: 21 Jan 2020, 3PM London/10AM New York/4PM Spain
We will discuss the potential of 3D printing of biomaterials and cells and maturing them in a bioreactor to create functional skin in the lab. We will talk about the requirements of biomaterials and introduce a versatile bioink technology. Furthermore, we will present a case study on a recently developed 3D printed in vitro skin model which utilises synthetically made but biologically active bioinks.
Key learning objectives:
- Understanding the benefits of additive manufacturing in tissue engineering.
- Getting an introduction to the different possibilities of biofabrication to create functional tissues.
- Understanding the requirements for optimal bioinks and the peptide technology behind the Biogelx™-INK product range.
- Case study: Development of a versatile skin model for future pharmaceutical research and clinical applications
The novel skin model is generated using Regemat3D™ extrusion-based bioprinter and Biogelx™-INK-GFOGER, which offers the advantage of creating a more accurate and standardised skin model. The uniformity and reproducibility achieved combining these technologies mean this novel in vitro skin model has the potential to act as a skin substitute in toxicity testing and potentially form the basis of a future cell therapy application.
There will be a live Q&A at the conclusion of the presentation.
José Manuel Baena, Ph.D – Founder and CEO at Regemat 3D
José Manuel Baena received a Ph.D. in Biomedicine from the University of Granada, Spain, MSc Engineering from Polytechnic University of Valencia, Spain and TU Braunschweig, Germany, and MSc from Oxford Brookes University, UK. As a biotech entrepreneur, Baena founded BRECA Health Care, a pioneer in 3D printed custom-made implants for orthopaedic surgery, and REGEMAT 3D, a leader in the bioprinting industry. He serves as scientific coordinator of the Tissue Engineering and 3D Printing Platform (PITI3D), IDIPAZ, Hospital Universitario de La Paz, Madrid, Spain and is a research associate in the group “Advanced therapies: differentiation, regeneration and cancer” IBIMER, CIBM, University of Granada, Spain. He is passionate about biomedicine and technology.
Chris Allan, Ph.D – Development Scientist at Biogelx
Chris is a chemist by training, who received his PhD from the University of Edinburgh in 2018. Since joining Biogelx, he has worked on the development of a range of bioinks based on the company’s proprietary peptide technology. Chris is also closely involved in many of the company’s collaborative projects which are ongoing with groups in academia and industry.
Mario Juárez Rodríguez MSc – Research associate at the Platform for Tissue Engineering and 3D Printing, La Paz University Hospital, Madrid
Mr. Juarez (MSc.) is a biotechnologist specialized in medical biotechnology and human bioengineering. His research has been focused in tissue engineering, synthetic biology and material science. Currently, he is working in skin tissue engineering in order to set up a facility to produce human skin for clinical applications (rare diseases, toxicology, cosmetics, cancer…)